CABOMETYX |
XL-184 FREE BASE |
XL-184 |
CABOZANTINIB |
BMS-907351 |
COMETRIQ |
CABOMETYX® |
BMS 907351 |
XL 184 |
BMS907351 |
COMETRIQ® |
XL184 |
pubchem.compound:25102847 |
chembl:CHEMBL2105717 |
rxcui:1363268 |
drugbank:08875 |
chemidplus:849217-68-1 |
Drug Categories | cytochrome p-450 cyp2c9 substrates |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Medullary thyroid cancer, Renal cell carcinoma |
Drug Class | Kinase Inhibitors |
Drug Categories | amines |
Drug Categories | aniline compounds |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | kinase inhibitor |
Drug Categories | tyrosine kinase inhibitors |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Details of the Assay for Interaction | In a biochemical assay. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
n/a |
inhibitor (inhibitory) |
Indication/Tumor Type | gastrointestinal stromal tumor |
Response Type | sensitive |
Approval Status | Preclinical |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
n/a |
Drug family | Pan-kinase inhibitor |
Alteration | HGF:over |
n/a |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted – sensitive |
Approval Status | Preclinical |
n/a |
Drug family | Pan-kinase inhibitor |
Alteration | ABL1:V299L |
CABOZANTINIB | DrugBank Drug Name |
849217-68-1 | CAS Number |
Cabometyx | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
CABOZANTINIB | Generic Name |
COMETRIQ | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Medullary thyroid cancer, Renal cell carcinoma |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CABOZANTINIB | Primary Drug Name |
CABOZANTINIB | Drug Generic Name |
COMETRIQ | Drug Trade Name |
CABOZANTINIB | GuideToPharmacology Ligand Name |
CHEMBL2105717 | ChEMBL Drug ID |
D0IQ6P | TTD Drug ID |